AZ gets China nod for Tagrisso in first-line lung cancerAstraZeneca has scored another approval for one of its new drugs in China, this time getting a green Share XAZ gets China nod for Tagrisso in first-line lung cancerhttps://pharmaphorum.com/news/az-gets-china-nod-for-tagrisso-in-first-line-lung-cancer/
Nine for 2019: Opportunities for pharmaIn the last Nine for 2019 article, we reflected on the major challenges that are shaping the pharmaceutical Share XNine for 2019: Opportunities for pharmahttps://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/
China in the fast laneBrett Gardiner and Boon Yap from Research Partnership discuss access opportunities for novel therapies in the world’s hottest Share XChina in the fast lanehttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/research-partnership-pharma-market-access-china/
Pfizer strikes deal with Chinese online pharmacy JiankePfizer is set to implement a new retail, hospital services and internet healthcare strategy in China as part Share XPfizer strikes deal with Chinese online pharmacy Jiankehttps://pharmaphorum.com/news/pfizer-chinese-online-pharmacy-jianke/
Roche’s Alecensa fast-tracked in ChinaChina’s national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European Share XRoche’s Alecensa fast-tracked in Chinahttps://pharmaphorum.com/news/roches-alecensa-fast-tracked-china/
Chinese pharma contaminated with scandalsAnother batch of vaccines have been found “substandard”, just days after the second-largest pharmaceutical company in China admitted Share XChinese pharma contaminated with scandalshttps://pharmaphorum.com/news/chinese-pharma-contaminated-scandals/
China strives to lower cost of cancer drugs as disease rates soarChina is pushing domestic and overseas markets to lower the cost of cancer drugs to make them more Share XChina strives to lower cost of cancer drugs as disease rates soarhttps://pharmaphorum.com/news/china-cancer-drug-pricing/
Biotech eyes Chinese opportunities and seek local partnersBiotech companies see China as one of the biggest healthcare opportunities, but would need partnerships before approaching the Share XBiotech eyes Chinese opportunities and seek local partnershttps://pharmaphorum.com/news/biotech-china-partnerships/
Trump’s trade war with China could drive up US pharma costsNew tariffs on goods coming from China could hit the US pharmaceutical industry, according to a new analysis Share XTrump’s trade war with China could drive up US pharma costshttps://pharmaphorum.com/news/trumps-trade-war-with-china-could-drive-up-us-pharma-costs/
